Histocompatibility & Immunogenetics Laboratory (HLA Lab)

About the HLA Lab

The Histocompatibility and Immunogenetics Laboratory (HLA Lab) provides testing to support hematopoietic stem cell and solid organ transplantations by performing HLA genotyping in donors and recipients to assess the closeness of match and identify mismatches; chimerism testing to evaluate for post-transplant engraftment; HLA antibody testing to identify anti-HLA antibodies; and flow crossmatches to assess donor-recipient compatibility. In addition, the HLA Lab provides testing for transfusion medicine, as well as disease association and pharmacogenetics analysis.

The HLA Lab offers a full range of testing services to support hematopoietic stem cell and solid organ transplantations, transfusion medicine (blood product testing) and HLA-related disease association/pharmacogenetics analysis. We service Stanford Health Care, Lucile Packard Children’s Hospital Stanford and other transplant centers and hospitals in the Bay Area and beyond.

As part of Stanford Blood Center (SBC), the HLA Lab is accredited by ASHI, certified by CLIA, and licensed by the State of California for high-complexity testing.

Contact us

Phone: (650) 724-6742 or (650) 723-5548, Option 0
FAX: (650) 723-6350

Email: secure-HLAsupport@lists.stanford.edu

Mailing Address:
Stanford Blood Center — HLA Lab
3373 Hillview Avenue
Palo Alto, CA 94304

Director: M. Fernández-Viña, PhD, F(ACHI)

OUR SERVICES

Transplant and Disease Association Testing Services

  • HLA typing, HLA antibody testing, flow crossmatches and chimerism testing for solid organ and hematopoietic stem cell transplantations
  • HLA-related disease associations and pharmacogenetic testing
  • HLA platelet compatibility testing for platelet refractoriness

Research and Bio-repository

The HLA lab also has an active research and development program, and houses and curates a bio-repository of patient specimens.

Order Testing Services

Stanford Entities: Log in to EPIC with your Stanford credentials to order. Sample requirements and reasons for rejection are listed under the “Specimen” tab per each test type. For a list of services available in the EPIC system, click here.

Transplant Testing Services

HLA Disease Association Testing Services

Disease Association Panel

A battery of eleven HLA disease associated panels are currently available:

  1. Abacavir Hypersensitivity
  2. Allopurinol Hypersensitivity
  3. Spondyloarthropathies (Ankylosing Spondylitis, Reiter’s Syndrome, Juvenile Arthritis)
  4. Eye Disease HLA Association (Acute Anterior Uveitis, Behçet’s Disease, Birdshot chorioretinopathy)
  5. Carbamazepine Hypersensitivity
  6. Celiac Disease
  7. Narcolepsy
  8. Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
  9. Psoriasis
  10. HLA typing Custom Panel (at intermediate resolution)
  11. HLA NGS typing (Full High Resolution)

About the panel:

There are a number of HLA specificities known to be associated with certain diseases or drug-induced adverse reactions. The confirmation of presence or absence of HLA factors associated with each disease can make a significant impact in the diagnosis and/ or treatment of patients. Based on current literature, the Stanford Blood Center Histocompatibility and Immunogenetics Laboratory designed a Disease Association Panel of pre-selected HLA specificities to facilitate this test request.

When it will be available:

The Disease Association Panel request is currently available to order in Epic for Stanford Health Care providers. The selection of a specific disease or drug hypersensitivity automatically defaults to the pre-selected HLA typing request with flexibility to add additional specificities if desired.

For non-Stanford providers, the request is made via the Stanford HLA Laboratory request form (currently this form may be requested by calling the Laboratory at 650-724-6742 and faxing the form to 650-723-6350). We hope to provide an electronic request form in the near future.

Supplemental Information

The Disease Association Panel supplemental information document below is to be used by health providers as a reference when selecting the panel of interest as well as a guide to interpretation of the test results. Clinicians should refer to the supplemental information document for information on clinical indication, methodology, limitations, clinical background and references.

HLA Lab Medical Leadership

Marcelo Fernandez ViñaMarcelo Fernández-Viña, Ph.D., D (ABHI) is a Professor for the Department of Pathology at Stanford University Medical School and serves as co-Director of the Histocompatibility & Immunogenetics Laboratory at this institution. He has been working in the fields of Histocompatibility and Immunogenetics since 1982. He earned a degree in Biochemistry from the School of Basic Sciences in Rosario, Argentina, and his Ph.D. in Internal Medicine from the University of Buenos Aires Medical School in Argentina. Previously he held a position as a Professor in the Department of Laboratory Medicine at the University of Texas M.D. Anderson Cancer Center in Houston. He has 170 peer reviewed publications, many of them focusing on HLA variation in multiple world populations, identifying susceptibility and resistance factors for diseases and in the impact of HLA mismatches in allogeneic transplantation; and 59 book chapters. He served as expert Consultant for Donor Searches for NMDP and as President Elect, President and Past President of the American Society for Histocompatibility and Immunogenetics. He served as a member of the Board of Directors and the Executive Committee for the United Network for Organ Sharing. Currently, he serves as Co-Chair of the Immunobiology Committee of the CIBMTR; and is the Liaison between the American Society for Histocompatibility and Immunogenetics to the National Marrow Donor Program. He serves as HLA Expert Consultant for the NMDP for the HRSA contract and is a member of the Histocompatibility Advisory Group for NMDP. He is Councilor of the International Histocompatibility Workshop and a member of the WHO Nomenclature Committee for Factors of the HLA System, Section Editor of Human Immunology and an Advisory Board Member of the International Journal of Immunogenetics.

CONTACT

Email: marcelof@stanford.edu

More information about Marcelo Fernández-Viña:
https://med.stanford.edu/profiles/marcelo-fernandez-vina
https://stanfordbloodcenter.org/leadership/marcelo-fernandez-vina/


Alin Girnita, MD, PhD, comes to Stanford from the University of Cincinatti Academic Health Center where he served as Professor of Clinical Surgery and Director of the Transplant Immunology Division of the Hoxworth Blood Center. He earned his MD and PhD from University of Medicine andPharmacy, in Craiova, Romania. He pursued his post-doctoral research training in Transplant Immunopathology and a participated in a Fellowship in Histocompatibility and Immunogenetics at the University of Pittsburgh and “Thomas E. Starzl” Transplant Institute. While there, he assumed the role of Associate Director of Histocompatibility and Immunogenetics until moving to the University of Cincinatti in 2009.

 

CONTACT

Email: alin.girnita@stanford.edu

More information about Alin Girnita:
https://med.stanford.edu/profiles/alin-girnita
https://stanfordbloodcenter.org/leadership/alin-girnita/


Melody ZhangDr. Bing (Melody) Zhang is a Clinical Assistant Professor for the Department of Pathology at Stanford University Medical School, and serves as Assistant Medical Director for the Histocompatibility & Immunogenetics Laboratory. She is also an attending physician practicing at the Stanford Molecular Pathology service.

Dr. Zhang received her medical degree and a master’s degree in Medical Genetics from Shandong University School of Medicine. She pursued postdoctoral research training in the department of Pathology at Stanford University after immigrating to the US. She then went on to complete her residency training in Clinical Pathology, as well as fellowships in Molecular Genetic Pathology and Clinical Genomics here at Stanford. She is Board Certified in Clinical Pathology and Molecular Genetic Pathology.

During the time of her research and clinical training, she won multiple national and departmental awards, including Mary Rodes Gibson Memorial Award in Hemostasis & Thrombosis (American Society of Hematology), AMP Young Investigator Award (Association for Molecular Pathology), Charles B. Carrington Memorial Award (Stanford Pathology Research Retreat), and Department of Pathology Trainee Mentored Award in Precision Health (Stanford), etc. She served as a junior member on the College of American Pathologists Biochemical and Molecular Genetics Committee from 2016 to 2017. During this time, she led the development of NGS-based inherited cancer panel proficiency testing and participated in reviewing of the NGS checklist and NGS proficiency surveys.

Dr. Zhang’s primary research interest is development and application of molecular assays for the diagnosis and monitoring of patients in transplant medicine. Clinically, she is interested in contributing to further integration of HLA laboratory with other operations in the SBC as well as relevant services in the department of Pathology.

 

CONTACT

Email: mbzhang@stanford.edu

More information about Bing Melody Zhang:
https://med.stanford.edu/profiles/Bing%20Zhang
https://stanfordbloodcenter.org/leadership/bing-melody-zhang/

17th IHIW Sponsorship

In 2017, the Stanford Histocompatibility & Immunogenetics Laboratory hosted the 17th International Histocompatibility and Immunogenetics Workshop and Conference (17th IHIW) in Pacific Grove, California.

The 17th Workshop was held to further advance the continued international collaboration in research in HLA and Immunogenetics projects. The major goal was to define HLA and KIR genomics, map serologic epitopes using NGS and single antigen bead technologies, and develop robust research and clinical informatics tools for HLA and KIR.